<DOC>
	<DOCNO>NCT01111279</DOCNO>
	<brief_summary>The purpose study assess safety tolerability gpASIT+TM administer subcutaneously absence presence immunoregulating adjuvant grass pollen allergic patient .</brief_summary>
	<brief_title>Clinical Safety Tolerability Study gpASIT+TM gpASIT+TM/Immunoregulating Adjuvant Treat Seasonal Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Subject give write informed consent Age 18 50 year The subject good physical mental health accord his/her medical history , vital sign , clinical status Male non pregnant , nonlactating female Females unable bear child must documentation CRF ( i.e . tubule ligation , hysterectomy , post menopausal ( define minimum one year since last menstrual period ) ) Allergy diagnosis : A history seasonal allergic rhinoconjunctivitis ( SAR ) grass pollen season least two previous year A positive skin prick test ( wheal diameter ≥ 3 mm ) grasspollen mixture Specific IgE grass pollen ( RAST class 2 IgE &gt; 0.7 kU/l ) Asymptomatic perennial inhalant allergen even show hypersensitive skin prick test . Subjects current past immunotherapy ( time past ) A history hypersensitivity excipients Subjects require control medication asthma ( bronchodilator nebulised drug local systemic corticosteroid ) Subjects document evidence acute significant chronic sinusitis ( determined investigator ) Subjects history hepatic renal disease Subjects symptomatic perennial inhalant allergens Subjects rhinitis medicamentosa , nonspecific rhinitis ( food dye , preservative agent… ) Subject malignant disease , autoimmune disease ( family medical history autoimmune disease ) Any chronic disease , may impair subject 's ability participate trial ( i.e . severe congestive heart failure , active gastric duodenal ulcer , uncontrolled diabetes mellitus , etc… ) Subjects require betablockers medication Chronic use concomitant medication would affect assessment effectiveness trial medication ( e.g . tricyclic antidepressant ) Subject febrile illness ( &gt; 37.5°C , oral ) A know positive serology HIV1/2 , HBs antigen antiHCV antibodies The subject immunocompromised medication illness , receive vaccine , corticoid immunosuppressive medication within 1 month trial entry Receipt blood blood derivative past 6 month precede trial entry Regular consumption corticoid ( oral , topic nasal ) antihistaminic drug within 4 week precede trial Any consumption corticoid ( oral , topic nasal ) antihistaminic drug within 1 week precede trial Use longacting antihistamine Female subject pregnant , lactating , childbearing potential protected pregnancy sufficiently reliable method ( OCs , IUD ) Any condition could incompatible protocol understand compliance Subjects forfeit freedom administrative legal award guardianship Unreliable subject include noncompliant subject , subject know alcoholism drug abuse history serious psychiatric disorder well subject unwilling give inform consent abide requirement protocol Subjects without mean contact investigator rapidly case emergency , able contact rapidly investigator Participation another clinical trial and/or treatment experimental drug within 1 month trial start Subjects participate trial BTTgpASIT003 treat group</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>